Natco Pharma gets USFDA nod for two products
Updated:
Updated:
May 22, 2021 16:17 IST
Natco and Arrow will launch the approved product on agreed-upon launch dates in the future, a release said.
Share Article
AAA
Natco and Arrow will launch the approved product on agreed-upon launch dates in the future, a release said. Natco Pharma has received final approval from the U.S. Food and Drug Administration for abbreviated new drug applications (ANDA) for two products, including an anti-cancer drug for which the company and its marketing partner had settled a litigation with Celgene.
On Lenalidomide capsules, which is indicated in treatment of certain types of cancers, Natco said it has received final approval for 5mg, 10mg, 15mg, and 25mg strengths and tentative approval of the 2.5 mg and 20mg strengths.
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2021
News provided by
Share this article
SAN DIEGO, March 10, 2021 /PRNewswire/
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, today announced the publication of two abstracts that will be presented as electronic posters during Week 1 of the American Association for Cancer Research (AACR) Annual Meeting 2021, taking place virtually from April 10-15, 2021.
Details on the electronic posters and corresponding abstracts are shown below.
Title: Expanded access program of the PLK1 inhibitor onvansertib for treatment of patients with KRAS-mutant metastatic colorectal cancer
Introduction
Pleading requirements in federal courts, particularly in securities class action cases, have become increasingly difficult, if not impossible, to satisfy. On December 30, 2020, a U.S. district court in California granted the motion of the biopharmaceutical company, Nektar Therapeutics, Inc. (“Nektar” or “Company”)
1 and its named officers (collectively, “Defendants”) to dismiss Plaintiffs’ second-amended securities fraud complaint (“Complaint”) by means of an opinion that stretched, we believe, well beyond the applicable pleading rules and statutes. Being the second dismissal in the case, the court denied Plaintiffs representatives of a putative class of shareholders of Nektar stock a third chance to amend their Complaint.
IIT-M identifies alternative method for producing anti-cancer drug Camptothecin
IIT-M identifies alternative method for producing anti-cancer drug Camptothecin
25 February 2021 | News Developed a microbial fermentation process that can be an economically efficient and sustainable method of production to fulfil the market demand at large scale
IIT Madras (IIT-M) Researchers have now developed an alternative method of Camptothecin production to meet the demand and conserve the natural sources. To this effect, they developed a microbial fermentation process that can be an economically efficient and sustainable method of production to fulfil the market demand at large scale.
The research was led by Dr Smita Srivastava, Associate Professor, Department of Biotechnology, IIT Madras. This work was recently published in the reputed peer-reviewed international Journal of Scientific Reports (a Nature Research Publication).
Bevacizumab is a medication that has been used to treat various types of cancer since 2004. It works by slowing the formation of new blood vessels by inhibiting a growth factor known as VEGF.
Since the beginning of the COVID-19 pandemic, experts have constantly tried to repurpose drugs to treat patients and bring down risks of severe complications of this contagious viral disease. They have come up with many promising leads and many existing drugs that hare already being used to treat other conditions are now also being given to COVID patients. The results have been promising. Now, in a new development, experts say that a common cancer drug that is used in many types of cancers may bring down the risk of severe infection considerably.